title: Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson's disease.
abstract: Idiopathic Parkinson's disease is a neurodegenerative disorder that affects approximately 1 % of the population over 55 years of age. The disease manifests itself through motor and nonmotor symptoms induced mainly by the neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The possible mechanisms involved in this pathology include mitochondrial dysfunction, neuroinflammation, and oxidative stress. The present study evaluated the effects of the nonselective cyclooxygenase inhibitor ibuprofen on motor and depressive-like behavior induced by rotenone in rats. Rotenone (2.5 mg/kg, i.p., for 10 days) decreased tyrosine hydroxylase immunoreactivity in the SNpc, and ibuprofen treatment (15 mg/kg, p.o., for 22 days) blocked this impairment. We also found that rotenone-induced motor deficits (hypolocomotion) and depressive-like behavior, and ibuprofen was able to reverse these deficits. In addition to motor and nonmotor behaviors, we evaluated oxidative stress induced by rotenone. Rotenone administration depleted glutathione levels in the hippocampus and reduced catalase activity in both the hippocampus and striatum. Post treatment with ibuprofen blocked the depletion of glutathione induced by rotenone and increased the basal levels of this antioxidant in the striatum. Ibuprofen also restored catalase activity. The neuroprotective effects of ibuprofen against toxicity induced by rotenone appear to be attributable to its antioxidant properties, in addition to cyclooxygenase inhibition.
authors.affiliation: Pharmacology Department, Federal University of Paraná, Curitiba, Brazil.
authors.forename: Tiago
authors.initials: T
authors.lastname: Zaminelli
authors.forename: Raísa Wendhausen
authors.initials: RW
authors.lastname: Gradowski
authors.forename: Taysa Bervian
authors.initials: TB
authors.lastname: Bassani
authors.forename: Janaína Kohl
authors.initials: JK
authors.lastname: Barbiero
authors.forename: Ronise M
authors.initials: RM
authors.lastname: Santiago
authors.forename: Daniele
authors.initials: D
authors.lastname: Maria-Ferreira
authors.forename: Cristiane Hatsuko
authors.initials: CH
authors.lastname: Baggio
authors.forename: Maria A B F
authors.initials: MA
authors.lastname: Vital
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002374:Catalase / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000378:metabolism; D007052:Ibuprofen; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000523:psychology; D011897:Random Allocation; D017208:Rats, Wistar; D012402:Rotenone; D013482:Superoxide Dismutase / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D000975:Antioxidants; D012402:Rotenone; D002374:Catalase; D014446:Tyrosine 3-Monooxygenase; D013482:Superoxide Dismutase; D005978:Glutathione; D007052:Ibuprofen
references.citation: Nat Rev Neurol. 2011 Dec 26;8(1):35-47
references.pmid: 22198405
references.citation: J Cell Biol. 2011 Mar 7;192(5):873-82
references.pmid: 21383081
references.citation: J Agromedicine. 2008;13(1):37-48
references.pmid: 19042691
references.citation: Parkinsonism Relat Disord. 2006 May;12(4):228-38
references.pmid: 16488175
references.citation: Exp Neurol. 2003 Jan;179(1):9-16
references.pmid: 12504863
references.citation: Ann N Y Acad Sci. 2003 Jun;991:272-7
references.pmid: 12846993
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1104-14
references.pmid: 20547199
references.citation: Pharmacol Rep. 2012;64(5):1081-90
references.pmid: 23238465
references.citation: J Neurochem. 2003 Sep;86(6):1338-45
references.pmid: 12950443
references.citation: Behav Pharmacol. 1997 Nov;8(6-7):523-32
references.pmid: 9832966
references.citation: Exp Neurol. 2007 Jun;205(2):295-312
references.pmid: 17433296
references.citation: Neuroscience. 2013 Feb 12;231:420-31
references.pmid: 23159314
references.citation: Behav Brain Res. 2002 Nov 15;136(2):521-32
references.pmid: 12429415
references.citation: Int Clin Psychopharmacol. 2006 Jul;21(4):219-25
references.pmid: 16687993
references.citation: Ann Neurol. 2005 Dec;58(6):963-7
references.pmid: 16240369
references.citation: Biomaterials. 2006 Feb;27(6):937-46
references.pmid: 16118017
references.citation: Eur Neuropsychopharmacol. 2001 Jun;11(3):203-8
references.pmid: 11418279
references.citation: Brain Res Rev. 2006 Sep;52(2):201-43
references.pmid: 16647138
references.citation: Neurochem Res. 2009 Feb;34(2):304-10
references.pmid: 18612814
references.citation: Neurology. 2011 Mar 8;76(10):863-9
references.pmid: 21368281
references.citation: Inflamm Res. 2002 Mar;51(3):154-9
references.pmid: 12005206
references.citation: Mov Disord. 2013 Jan;28(1):24-30
references.pmid: 22927094
references.citation: Cold Spring Harb Perspect Med. 2012 Jan;2(1):a009381
references.pmid: 22315722
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5473-8
references.pmid: 12702778
references.citation: Exp Neurol. 2004 Jun;187(2):418-29
references.pmid: 15144868
references.citation: J Alzheimers Dis. 2012;30(1):183-208
references.pmid: 22406441
references.citation: Neurobiol Aging. 2012 Jan;33(1):197.e21-32
references.pmid: 20696495
references.citation: Int J Mol Med. 2007 Mar;19(3):517-21
references.pmid: 17273802
references.citation: Curr Pharm Des. 2012;18(36):5890-9
references.pmid: 22681168
references.citation: Neuroscience. 2012 Jun 1;211:51-76
references.pmid: 22108613
references.citation: Mol Psychiatry. 2006 Jul;11(7):680-4
references.pmid: 16491133
references.citation: Synapse. 2013 Aug;67(8):502-14
references.pmid: 23447126
references.citation: Neurotox Res. 2011 Feb;19(2):308-18
references.pmid: 20658274
references.citation: J Pharmacol Exp Ther. 2004 Aug;310(2):800-7
references.pmid: 15131242
references.citation: Free Radic Biol Med. 1993 Jan;14(1):85-90
references.pmid: 8384151
references.citation: J Neurochem. 1998 Oct;71(4):1635-42
references.pmid: 9751197
references.citation: J Neurosci. 2000 Jan 1;20(1):1-7
references.pmid: 10627575
references.citation: Neurotox Res. 2012 Apr;21(3):291-301
references.pmid: 21953489
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):157-67
references.pmid: 21667279
references.citation: J Neurochem. 2003 Feb;84(3):491-502
references.pmid: 12558969
references.citation: Anal Biochem. 1968 Oct 24;25(1):192-205
references.pmid: 4973948
references.citation: J Pharmacol Exp Ther. 1998 Jan;284(1):215-21
references.pmid: 9435181
references.citation: Arch Gen Psychiatry. 1983 Apr;40(4):405-6
references.pmid: 6838321
references.citation: Free Radic Biol Med. 2013 Sep;62:111-120
references.pmid: 23328732
references.citation: J Comp Neurol. 2004 Oct 25;478(4):418-26
references.pmid: 15384065
references.citation: Behav Brain Res. 2002 Oct 17;136(1):317-24
references.pmid: 12385818
references.citation: Arthritis Rheum. 1999 Dec;42(12):2561-8
references.pmid: 10616001
references.citation: Eur J Biochem. 1974 Sep 16;47(3):469-74
references.pmid: 4215654
references.citation: Anal Biochem. 1992 May 1;202(2):384-9
references.pmid: 1519766
references.citation: Neuron. 2003 Sep 11;39(6):889-909
references.pmid: 12971891
references.citation: J Neuropathol Exp Neurol. 2004 Sep;63(9):901-10
references.pmid: 15453089
references.citation: FASEB J. 2004 Apr;18(6):717-9
references.pmid: 14766796
references.citation: Crit Rev Neurobiol. 1999;13(1):45-82
references.pmid: 10223523
references.citation: Neurobiol Dis. 2009 May;34(2):279-90
references.pmid: 19385059
references.citation: Neurosci Res. 2012 Oct;74(2):80-90
references.pmid: 22902554
references.citation: J Neurosci. 2000 Aug 15;20(16):6309-16
references.pmid: 10934283
references.citation: Neurosci Lett. 2002 Sep 6;329(3):354-8
references.pmid: 12183047
references.citation: Eur J Pharmacol. 1978 Feb 15;47(4):379-91
references.pmid: 204499
references.citation: J Biomed Biotechnol. 2012;2012:845618
references.pmid: 22536024
references.citation: Environ Health Perspect. 2011 Jun;119(6):866-72
references.pmid: 21269927
references.citation: Biochim Biophys Acta. 2001 Jul 2;1506(1):79-87
references.pmid: 11418099
references.citation: Neurosci Lett. 2000 Aug 11;289(3):201-4
references.pmid: 10961664
references.citation: Biofactors. 2012 Nov-Dec;38(6):395-7
references.pmid: 22826171
references.citation: Nat Neurosci. 2000 Dec;3(12):1301-6
references.pmid: 11100151